Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients (2021) Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, et al. Conference contribution Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS)-30-months Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Conaghan P, Naredo E, Carron P, Burgos-Vargas R, et al. Conference contribution Guselkumab (TREMFYA (R)) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study (2021) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease P, Shawi M, Cua D, et al. Conference contribution Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study (2021) D'Agostino MA, Schett G, Gaillez C, Guerrero C, Hanova P, Cazenave T, Stoenoiu MS, et al. Conference contribution Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study (2021) Mease P, Deodhar A, Merola J, Mcinnes I, Assudani D, Bajracharya R, Coarse J, et al. Conference contribution Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function (2021) Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Kellner H, Kiltz U, Rech J, et al. Conference contribution Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial (2021) Venhoff N, Schmidt W, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study (2021) Kaeley G, Schett G, Conaghan P, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry (2021) Risser L, Witte T, Bartz-Bazzanella P, Von Der Decken C, Knitza J, Fekete SP, Zink A, et al. Conference contribution